TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
Ascendis Pharma presented pooled Phase 2/3 data showing TransCon PTH delivered sustained kidney-function improvements in hypoparathyroidism patients treated up to 5 years. Mean eGFR rose 7.2 mL/min/1.73 m2 by Week 26 and 9.6 by Week 52, with 68.9% of patients achieving clinically meaningful gains; eGFR stayed stable through Week 266. By final visit, 98% of patients were off active vitamin D and 95% off therapeutic calcium, with no new safety signals.
Key figures
- Drug Name
- TransCon PTH (palopegteriparatide)
- Phase Of Trial
- Phase 2 (PaTH Forward) and Phase 3 (PaTHway)
- Pooled patients
- 141
- Treated patients
- 139
- Calcium independence
- 95%
- Normal serum calcium
- 8.9 mg/dL
- Urine calcium week52
- 170 mg/day
- Urine calcium baseline
- 396 mg/day
- Vitamin d independence
- 98%
- Egfr improvement week26
- 7.2 mL/min/1.73 m2
- Egfr improvement week52
- 9.6 mL/min/1.73 m2
- Egfr slope week52 to week266
- 0.28 mL/min/1.73 m2/year
- Patients with egfr gain 5plus week52
- 68.9%
- Patients with egfr gain 10plus week52
- 49.6%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.